New two-year data confirm Roche's Vabysmo improves vision

Swiss pharma giant Roche (ROG: SIX) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab) in neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of vision loss.

Neovascular AMD affects nearly 20 million people globally and can require treatment with eye injections every one to two months. The two-year data were presented at the 2022 American Society of Retina Specialists Annual Scientific Meeting.

“These longer-term results reinforce confidence in Vabysmo and support its continued use in people with neovascular AMD,” said Dr Levi Garraway, chief medical officer and head of global product development. “With the potential to require fewer injections over time, Vabysmo continues to represent an important step forward for people with vision-threatening retinal conditions, and these data exemplify our commitment to redefining standards of care and reducing treatment burden,” he noted.

In the TENAYA and LUCERNE studies, at two years: